Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Top Cited Papers
- 15 January 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (2) , 558-567
- https://doi.org/10.1200/jco.2001.19.2.558
Abstract
PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for tre...Keywords
This publication has 26 references indexed in Scilit:
- Mechanisms of bone metastasisCancer, 1997
- Treatment of Cancer-Associated HypercalcemiaArchives of internal medicine (1960), 1994
- Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosagesThe American Journal of Medicine, 1993
- Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.Journal of Clinical Oncology, 1992
- Cancer-Associated Hypercalcemia: Morbidity and MortalityAnnals of Internal Medicine, 1990
- Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusionsJournal of Bone and Mineral Research, 1989
- Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.BMJ, 1987
- Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.Journal of Clinical Oncology, 1986
- The Hypercalcemia of CancerNew England Journal of Medicine, 1984
- Biochemical Evaluation of Patients with Cancer-Associated HypercalcemiaNew England Journal of Medicine, 1980